Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 578,409 shares of the company’s stock after acquiring an additional 12,906 shares during the period. Charles Schwab Investment Management Inc. owned 0.97% of Protagonist Therapeutics worth $22,327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Cavalier Investments LLC grew its position in Protagonist Therapeutics by 4.3% during the 4th quarter. Cavalier Investments LLC now owns 31,252 shares of the company’s stock worth $1,206,000 after purchasing an additional 1,296 shares during the period. Illinois Municipal Retirement Fund boosted its stake in shares of Protagonist Therapeutics by 15.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 33,509 shares of the company’s stock worth $1,293,000 after acquiring an additional 4,385 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Protagonist Therapeutics by 39.7% during the 4th quarter. Los Angeles Capital Management LLC now owns 31,366 shares of the company’s stock worth $1,211,000 after acquiring an additional 8,920 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Protagonist Therapeutics by 9.7% during the 4th quarter. Bank of New York Mellon Corp now owns 390,788 shares of the company’s stock worth $15,084,000 after acquiring an additional 34,455 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new position in Protagonist Therapeutics in the 4th quarter valued at about $4,053,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Stock Up 2.8 %

Shares of PTGX stock opened at $54.52 on Wednesday. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60. The stock has a market capitalization of $3.35 billion, a PE ratio of 20.50 and a beta of 2.34. The firm has a 50 day moving average of $40.25 and a two-hundred day moving average of $42.39.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $2.07. The business had revenue of $170.64 million during the quarter, compared to analysts’ expectations of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Truist Financial raised their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $54.00 price target on shares of Protagonist Therapeutics in a report on Monday, March 10th. Wedbush reiterated an “outperform” rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, March 11th. Finally, BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $62.56.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 30,514 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares of the company’s stock, valued at $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Asif Ali sold 24,903 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the sale, the chief financial officer now directly owns 62,821 shares of the company’s stock, valued at approximately $3,689,477.33. This trade represents a 28.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 60,776 shares of company stock valued at $3,368,010. Insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.